Pharming Group announces the placement of €100 million convertible bonds due 2029
April 18, 2024 09:04 ET
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
April 18, 2024 02:00 ET
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
April 08, 2024 01:00 ET
|
Pharming Group N.V.
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming...
Pharming Group announces the 2024 Annual General Meeting of Shareholders
April 04, 2024 02:30 ET
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of...
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
April 04, 2024 01:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended...
Pharming Group to participate in April investor conferences
April 03, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports fourth quarter and full year 2023 financial results
March 14, 2024 02:00 ET
|
Pharming Group N.V.
Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to...
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
February 29, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
Pharming Group to participate in February investor conferences
February 08, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
January 08, 2024 01:00 ET
|
Pharming Group N.V.
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end ...